Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer

Table 1

Clinical characteristic of patients between high and low expressions of TBC1D10C.

	Overall	TBC1D10C		value
		High expression	Low expression
	898	449	449
ER_Status (%)				0.065
Negative	196 (21.8)	112 (24.9)	84 (18.7)
Positive	658 (73.3)	314 (69.9)	344 (76.6)
Unknown	44 (4.9)	23 (5.1)	21 (4.7)
PR_Status (%)				0.954
Negative	280 (31.2)	142 (31.6)	138 (30.7)
Positive	571 (63.6)	284 (63.3)	287 (63.9)
Unknown	47 (5.2)	23 (5.1)	24 (5.3)
HER2_Status (%)				0.007
Negative	674 (75.1)	323 (71.9)	351 (78.2)
Positive	122 (13.6)	60 (13.4)	62 (13.8)
Unknown	102 (11.4)	66 (14.7)	36 (8.0)
PAM50 subtype (%)				<0.001
Basal	118 (13.1)	61 (13.6)	57 (12.7)
Her2	62 (6.9)	30 (6.7)	32 (7.1)
LumA	362 (40.3)	160 (35.6)	202 (45.0)
LumB	166 (18.5)	59 (13.1)	107 (23.8)
Unknown	190 (21.2)	139 (31.0)	51 (11.4)
M stage (%)				0.004
M0	882 (98.2)	447 (99.6)	435 (96.9)
M1	16 (1.8)	2 (0.4)	14 (3.1)
N stage (%)				0.013
N0	413 (46.0)	212 (47.2)	201 (44.8)
N1	304 (33.9)	142 (31.6)	162 (36.1)
N2	119 (13.3)	53 (11.8)	66 (14.7)
N3	62 (6.9)	42 (9.4)	20 (4.5)
T stage (%)				0.09
T1	236 (26.3)	128 (28.5)	108 (24.1)
T2	532 (59.2)	259 (57.7)	273 (60.8)
T3	101 (11.2)	53 (11.8)	48 (10.7)
T4	29 (3.2)	9 (2.0)	20 (4.5)
TNM stage (%)				0.051
I	157 (17.5)	80 (17.8)	77 (17.1)
II	526 (58.6)	269 (59.9)	257 (57.2)
III	201 (22.4)	98 (21.8)	103 (22.9)
IV	14 (1.6)	2 (0.4)	12 (2.7)
Age [IQR]	58.00; [48.00, 67.00]	58.00; [49.00, 66.00]	58.00; [48.00, 67.00]	0.92
TMB [IQR]	0.97; [0.63, 1.78]	0.93; [0.58, 1.89]	1.01; [0.66, 1.71]	0.412
Stromal_score [IQR]	414.52; [-163.90, 838.41]	554.52; [90.80, 967.12]	204.14; [-339.70, 700.80]	<0.001
Immune_score [IQR]	121.41; [-362.02, 691.89]	638.86; [170.02, 1224.44]	-287.32; [-614.74, 72.88]	<0.001

ER: estrogen receptor; PR: progesterone receptor; HER2: human epithelial growth factor receptor 2. IQR: interquartile range. TMB: tumor mutational burden. : sample numbers.